The integration of ICIs targeting PD-1/PD-L1 and CTLA-4 pathways in numerous trials signals a significant shift towards using the immune system against HCC, diverging from traditional treatment methods. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.